<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583800</url>
  </required_header>
  <id_info>
    <org_study_id>2019_66</org_study_id>
    <secondary_id>2020-A01452-37</secondary_id>
    <nct_id>NCT04583800</nct_id>
  </id_info>
  <brief_title>Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes</brief_title>
  <acronym>PreciDIAB-H&amp;B</acronym>
  <official_title>Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes : Longitudinal Cohort Study of Immuno-inflammation, Cardiac Energetics and Cognition.PreciDIAB-HEART&amp;BRAIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a risk factor of heart failure and cognitive decline. Heart failure at its&#xD;
      early stage is often silent. At present, primary prevention for heart failure is not&#xD;
      available. Our aim is to identify diabetic patients at risk of heart failure in order to&#xD;
      develop personalized preventive strategies.&#xD;
&#xD;
      Type 2 diabetes is vascular and metabolic risk factor for cognitive decline though a direct&#xD;
      lesional effect but also through an interaction with underlying neurodegenerative lesions.&#xD;
      Our aim is to identify diabetic patients at risk of cognitive decline in order to develop&#xD;
      personalized preventive strategies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Heart failure (≥ stade B).</measure>
    <time_frame>at 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive decline (composite endpoint)</measure>
    <time_frame>at 48 months</time_frame>
    <description>a decrease in cognitive performance quantified at 1.5 standard deviation on at least 1 neuropsychological test within a cognitive domain (attention and speed of information processing, memory, executive functions) compared to the neuropsychological assessment performed at inclusion.&#xD;
Appearance of dementia defined as a cognitive disorder highlighted in the neuropsychological evaluation carried out at the end of the study leading to a loss of functional autonomy in activities of daily living defined by the loss of at least 1 point on the activities of daily living ADL scale (DSM V).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardio-neuro-vascular events</measure>
    <time_frame>at 48 months</time_frame>
    <description>cardioneurovascular event (composite endpoint) defined by the occurrence of death from any cause, myocardial infarction, stroke (ischemic or hemorrhagic), acute limb ischemia or a doubling of creatinine.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Heart Failure</condition>
  <condition>Cognitive Decline</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        People with type 2 diabetes and free of heart failure (≥stade B).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Persons able to understand and object to the information provided.&#xD;
&#xD;
          -  Type 2 diabetic patient free of heart failure ≥stade B&#xD;
&#xD;
          -  Patient affiliated with a social security scheme.&#xD;
&#xD;
          -  Patient agreeing to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with dementia&#xD;
&#xD;
          -  Patient with at least one of the criteria for heart failure ≥stade B&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Cordonnier, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Cordonnier, MD,PhD</last_name>
    <phone>0320445962</phone>
    <email>precidiab_heart_brain@chru-lille.fr</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Stroke Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

